COMMUNIQUÉS West-GlobeNewswire

Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
25/08/2025
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D. The facility will create more than 1,900 jobs and support the production of next-generation metabolic [...]
Protecting healthcare workers protects us all:
25/08/2025
Canadian coalition gets overwhelming support backing stronger protections for healthcare workers in updated CSA respirator standard TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Canadian healthcare workers deserve the same [...]
Protéger le personnel de la santé, c’est nous protéger tous
25/08/2025
Une coalition canadienne obtient un appui massif en faveur des mesures de protection renforcées pour les travailleurs de la santé, prévues dans la mise à jour de la norme sur les appareils de protection respiratoire de [...]
Baylor Genetics to Showcase RNA Sequencing Breakthroughs for Rare Disease Diagnosis at 2025 AGBT Precision Health Meeting
25/08/2025
Company to Highlight the Role of Precision Diagnostics in Transforming Rare and Undiagnosed Disease Care HOUSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of [...]
Husband Material Ministries Announces New Book by Drew Boa: "Outgrow Porn: Find Lasting Freedom Without Fighting an Exhausting Battle—A Man's Guide to Healing"
25/08/2025
Empowering Men to Overcome Pornography Addiction Colorado Springs, CO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Husband Material Ministries , a leading nonprofit organization dedicated to helping men find lasting freedom from [...]
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
25/08/2025
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other [...]
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
25/08/2025
HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4:15 p.m. ET. Attendees will [...]
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
25/08/2025
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more effective treatment [...]
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
25/08/2025
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress [...]
Safety Shot Secures $30 Million Strategic Investment From BONK Core Team and FalconX
25/08/2025
SCOTTSDALE, AZ, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today announced it has successfully priced a $30 million financing , anchored by a consortium of [...]
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
25/08/2025
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More than 50 million [...]
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
25/08/2025
Current Clinical Trial Focus is MSS Colorectal Cancer, Ovarian Clear-Cell Carcinoma, and Soft-Tissue Sarcoma DENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the [...]
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
25/08/2025
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") ( [...]
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
25/08/2025
Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors [...]
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
25/08/2025
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29 th - [...]
Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4
25/08/2025
$52M Series A raised in 2024, led by Eight Roads and 3E Bioventures SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved [...]
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
25/08/2025
First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage [...]
4DMT to Participate in Upcoming Investor Conferences
25/08/2025
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
25/08/2025
- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering [...]

Pages